News - Diabetes

Filter

Current filters:

Diabetes

Popular Filters

400 to 424 of 429 results

US FDA advisory gives thumbs down to B-MS and AstraZeneca diabetes drug dapagliflozin on safety issues

20-07-2011

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesNorth AmericaPharmaceuticalRegulation

European Commission and Australia OK Bristol-Myers Yervoy and Novo Nordisk’s FlexTouch

15-07-2011

Following a recent positive recommendation from the European Medicine Agency’s advisory panel, Bristol-Myers…

Bristol-Myers SquibbDiabetesEuropeFlexTouchNovo NordiskOncologyPharmaceuticalRegulationYervoy

Amylin and Lilly to re-file Bydureon with US FDA sooner than expected with new tQT data

11-07-2011

Amylin Pharmaceuticals (Nasdaq: AMLN), Eli Lilly (NYSE: LLY) and Alkermes (Nasdaq: ALKS) have announced…

AlkermesAmylinBydureonDiabetesEli LillyPharmaceuticalRegulationResearch

Roche returns rights to SGLT2 inhibitor CSG452 for diabetes to Chugai

06-07-2011

Swiss drug major Roche (ROG: SIX) said yesterday that it will return its development and marketing rights…

Chugai PharmaceuticalDiabetesLicensingPharmaceuticalRoche

Highlights from American Diabetes Association meeting

27-06-2011

There was a batch of good news coming out of the American Diabetes Association (ADA) 71st annual scientific…

ApidraAstraZenecaBristol-Myers SquibbdapagliflozinDiabetesLantusLyxumiaNovo NordiskOnglyzaPharmaceuticalResearchSanofiVictoza

Eli Lilly gets EU approval for long-acting diabetes drug Bydureon

22-06-2011

In what was excellent news for all three companies following rejections of the drug by US regulators,…

AlkermesAmylinBydureonDiabetesEli LillyEuropePharmaceuticalRegulation

Boehringer gains global rights to Zealand’s diabetes/obesity compounds in 376 million-euro deal

17-06-2011

German independent drug major Boehringer Ingelheim has signed an exclusive global licence and collaboration…

Boehringer IngelheimDiabetesLicensingMetabolicsPharmaceuticalResearchZealand Pharma

Bladder cancer risk of Takeda’s Actos now highlighted by US FDA

16-06-2011

The latest bad news for Japan’s largest drugmaker, Takeda Pharmaceutical (TYO: 4502) came last night…

ActosDiabetesNorth AmericaPharmaceuticalRegulationTakeda Pharmaceuticals

Boehringer Ingelheim and Lilly begin US roll-out of diabetes drug Tradjenta

16-06-2011

German independent drug major Boehringer Ingelheim and USA-based Eli Lilly (NYSE: LLY) announced yesterday…

Boehringer IngelheimDiabetesEli LillyMarkets & MarketingNorth AmericaPharmaceuticalTradjenta

France suspends sales of Takeda’s Actos on cancer risk concerns

10-06-2011

Sales of blockbuster diabetes drug Actos (pioglitazone), from Japan’s leading drugmaker Takeda Pharmaceuticals…

ActosDiabetesEli LillyEuropePharmaceuticalRegulationTakeda Pharmaceuticals

Asterand licenses diabetes assay platform from Capsant Neurotech

09-06-2011

Asterand (LSE: ATD), a provider of human tissue and cell-based services to pharmaceutical and biotechnology…

AsterandBiotechnologyCapsant NeurotechnologiesDiabetesLicensing

Tianyin granted production license for diabetes drug Gliclazide by China's SFDA

02-06-2011

Tianyin Pharmaceutical (NYSE Amex: TPI), a China-based pharmaceutical company that specializes in patented…

Asia-PacificDiabetesGliclazidePharmaceuticalRegulationTianyin Pharma

Positive Ph III results from Sanofi GetGoal Program on Lyxumia

01-06-2011

French drug major Sanofi (Euronext: SAN) announced today that new results from a Phase III study showed…

DiabeteslixisenatideLyxumiaPharmaceuticalResearchSanofiZealand Pharma

GlaxoSmithKline’s diabetes drug Avandia to be restricted on US market

20-05-2011

As part of a US Food and Drug Administration re-assessment of UK drug giant GlaxoSmithKline’s troubled…

AvandiaDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulation

US cancer drug use and spending to rise sharply by 2013, followed by diabetes and CNS, says Medco

19-05-2011

Expensive new cancer drugs treating increasing numbers of patients could drive cancer drug spending by…

DiabetesMarkets & MarketingNeurologicalNorth AmericaOncologyPharmaceuticalPricing

Amylin sues Eli Lilly, alleging anti-competitive activity

17-05-2011

San Diego, USA-based Amylin Pharmaceuticals (Nasdaq: AMLN) has filed a law suit against drug major Eli…

AmylinBoehringer IngelheimByettaDiabetesEli LillyLegallinagliptinPharmaceuticalTradjenta

400 to 424 of 429 results

Back to top